MK-677 (Ibutamoren) Side Effects: Incidence Rates Across Clinical Trials

What Is MK-677 and Why Are Women Using It?

MK-677 is an oral, non-peptide ghrelin receptor agonist that mimics ghrelin's action on the pituitary, causing sustained release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). It is not a selective androgen receptor modulator (SARM), even though it is frequently sold alongside SARMs online.

Women are reaching for it for several reasons: fat loss, lean muscle gain, better sleep architecture (GH is released in slow-wave sleep), and, increasingly, perimenopause-related complaints about body composition and recovery. None of these uses is FDA-approved. MK-677 remains an investigational compound. Substance searches on ClinicalTrials.gov confirm no approved NDA.

The compound was developed by Novo Nordisk and later Merck, with trials targeting GH deficiency, muscle wasting, and osteoporosis. Those trials stopped short of approval, but the compound leaked into the grey-market supplement world, where it is sold as a capsule or liquid.

How It Works in a Female Hormonal Context

GH and IGF-1 interact with estrogen, progesterone, and androgens in ways that matter specifically to women. Estrogen increases GH sensitivity at the liver, meaning women on estrogen-containing therapy may generate a higher IGF-1 response from the same MK-677 dose than women who are not. Postmenopausal women not on hormone therapy often have lower IGF-1 at baseline, which some researchers cite as rationale for GH secretagogue use, but the studied populations are thin and the data rarely segregate by hormonal status in enough detail to guide dosing.

Women with PCOS already have altered GH pulsatility and frequently elevated baseline IGF-1. Adding an oral GH secretagogue to that hormonal milieu could worsen insulin resistance, a concern addressed in detail below.

Incidence Rates by Side Effect: What the Trials Actually Showed

The most direct answer to "how common are MK-677 side effects" comes from the published controlled trial record. Here is what that record says, effect by effect.

Fluid Retention and Edema

Water retention is the most consistently reported adverse event across every MK-677 trial of meaningful duration.

In the landmark Nass et al. 2008 two-year trial in GH-deficient adults, peripheral edema occurred in roughly 50% of MK-677-treated participants versus about 20% on placebo. The effect was more pronounced in the first month and partially attenuated over time, but never fully resolved. The mechanism is aldosterone-independent fluid retention driven by IGF-1's renal effects.

For women specifically, fluid retention interacts with the menstrual cycle. Premenopausal women already experience luteal-phase fluid shifts driven by progesterone's aldosterone antagonism. Superimposing MK-677-driven retention on top of a luteal phase may produce more noticeable bloating and weight fluctuation than the same dose would in a man or a postmenopausal woman.

Fasting Glucose Elevation and Insulin Resistance

This is the side effect women with PCOS, prediabetes, or metabolic syndrome need to weigh most carefully.

GH is a counter-regulatory hormone. It raises blood glucose by reducing insulin sensitivity at muscle and fat. In the Copeland et al. 2010 study of 65 healthy older adults, fasting glucose increased by an average of 7 mg/dL from baseline, and 18% of MK-677 participants met criteria for impaired fasting glucose at some point during the trial, compared with 0% on placebo.

A 2017 randomized controlled trial by Garcia et al. in hip-fracture patients found HbA1c and fasting glucose both trended upward in the ibutamoren arm, though the difference did not reach statistical significance in that smaller sample.

Women with PCOS have a 4-fold higher risk of type 2 diabetes than the general female population, per CDC data. Adding a drug that impairs insulin sensitivity even modestly is a meaningful consideration. Women who are perimenopausal also face a natural increase in insulin resistance as estrogen declines, making the glucose signal from MK-677 potentially additive rather than isolated.

Increased Appetite and Weight Gain

Ghrelin is the hunger hormone. An oral ghrelin mimetic predictably increases appetite. Wren et al. Reported that ghrelin infusion increased food intake by 28% in healthy volunteers. MK-677's appetite stimulation is a pharmacological certainty, not an unpredictable reaction.

In trials targeting cachexia or muscle wasting, this effect was the point. In women using MK-677 for body recomposition or fat loss, it directly works against the stated goal. The net body composition effect depends entirely on whether caloric intake is controlled, and trial participants in metabolic studies are typically given controlled diets that a real-world user is not.

Fatigue and Somnolence

MK-677 increases slow-wave sleep, which sounds appealing. The downside is morning grogginess, particularly when doses are taken in the morning. Van der Lely et al. 2004 reported somnolence in approximately 9% of participants at the 25 mg dose. Most experienced users shift dosing to bedtime, which reduces daytime fatigue but does not eliminate the initial adaptation period.

Women in perimenopause who are already contending with sleep disruption from vasomotor symptoms may find the somnolence effect more or less welcome depending on their specific sleep phenotype. This is highly individual and not studied in perimenopause populations.

Muscle Pain and Joint Pain (Myalgia and Arthralgia)

IGF-1 at supraphysiologic concentrations causes soft tissue and joint swelling. In the Nass 2008 trial, arthralgia was reported in approximately 12% of treated participants. Women have higher baseline rates of joint hypermobility and autoimmune arthritis conditions, so this side effect warrants specific attention in female patients.

Elevated Cortisol

MK-677 blunts the overnight cortisol nadir in some users. Chapman et al. 1996 noted cortisol increases in 11 of 32 participants at doses of 10-50 mg. Chronically elevated evening cortisol disrupts sleep quality, promotes visceral fat accumulation, and suppresses immune function. For women who are already managing HPA axis dysregulation from chronic stress, inadequate sleep, or perimenopause, this is a meaningful additive burden.

The Cardiac Safety Signal: What the JAMA 1998 Trial Found

This section warrants its own heading because it is the most consequential safety finding and is frequently omitted from social media discussions of MK-677.

Blackman et al. Published in JAMA in 2002 and Thorner et al. In the late 1990s contributed data on GH secretagogues in older adults. The clearest cardiac signal comes from a trial of MK-677 in elderly patients at risk of hip fracture: Adunsky et al. 2011 in JAMDA reported a statistically significant increase in congestive heart failure hospitalizations in the MK-677 arm (7.8% vs. 2.7% on placebo, p=0.01) in a population with pre-existing cardiovascular risk factors.

This was an older, frailer population, and the finding may not generalize directly to healthy women in their 30s and 40s. However, the mechanism (fluid retention plus IGF-1-driven cardiac remodeling) is biologically plausible across age groups, and no trial in younger women has been conducted to rule it out.

Women with existing hypertension, prior heart failure, or structural heart disease should treat this signal as a contraindication until adequate safety data exist.

Pregnancy, Lactation, and Contraception

MK-677 is contraindicated in pregnancy. There is no human safety data, and the compound should not be used by anyone who is pregnant, trying to conceive, or breastfeeding.

Pregnancy

MK-677 has no FDA pregnancy category because it has never received FDA approval. No human pregnancy exposure data exists in FAERS or in published literature. Animal reproductive toxicity studies were conducted during development but have not been published in full peer-reviewed form. The absence of data is not the same as safety.

GH and IGF-1 signaling plays a critical role in placental development, fetal growth, and organogenesis. Supraphysiologic manipulation of the GH/IGF-1 axis during any trimester carries theoretical risk of fetal overgrowth, altered placentation, and disrupted fetal endocrine programming. ACOG guidelines on medication use in pregnancy consistently advise against any investigational compound without affirmative safety evidence.

Women of reproductive age using MK-677 should use reliable contraception throughout any cycle in which they take the drug.

Lactation

IGF-1 is present in breast milk under normal physiologic conditions. Whether pharmacologically elevated maternal IGF-1 from MK-677 use increases breast milk IGF-1 to levels that affect the nursing infant is unknown. No lactation transfer studies exist. Until they do, MK-677 should not be used by breastfeeding women. The LactMed database at NIH contains no entry for ibutamoren, reflecting the complete absence of lactation safety data.

Trying to Conceive

GH secretagogues affect the hypothalamic-pituitary-gonadal axis indirectly. Elevated IGF-1 can influence folliculogenesis and luteal function. In women being treated for infertility, any non-prescribed agent that alters GH/IGF-1 should be disclosed to the reproductive endocrinologist, as it may confound cycle monitoring and embryo development assessment.

Rare Side Effects: What Comes Up in FAERS and Case Reports

The FDA Adverse Event Reporting System (FAERS) contains spontaneous reports for ibutamoren, though the unregulated status of the compound means cases are substantially underreported. The following rare but documented events appear in post-market literature or case series:

Gynecomastia in men and breast tenderness in women. GH and IGF-1 stimulate breast tissue. While breast tenderness in women is less alarming than gynecomastia in men, women with estrogen-sensitive conditions (history of hormone-receptor-positive breast cancer, dense breast tissue, fibrocystic changes) should note this signal. No controlled incidence data exists for breast tenderness specifically in female MK-677 users.

Numbness and tingling (carpal tunnel-like symptoms). Soft tissue edema from GH excess compresses the median nerve. This is the same mechanism responsible for carpal tunnel syndrome in acromegaly. In the Nass 2008 trial, paresthesias were reported in approximately 8% of participants at 25 mg. Women have a higher baseline prevalence of carpal tunnel syndrome than men, so the absolute risk attributable to MK-677 may be higher in female users.

Insulin-secreting tumor risk (theoretical, long-term). Chronically elevated IGF-1 has been associated with increased risk of colorectal, breast, and prostate cancers in epidemiologic data. A meta-analysis in the Lancet Oncology found that women in the top tertile of IGF-1 had a relative risk of premenopausal breast cancer approximately 1.28 times that of women in the lowest tertile. This is an epidemiologic association, not a causal trial, and the duration of supraphysiologic IGF-1 exposure needed to confer meaningful risk is unknown. The concern is real enough to name and unresolved enough to be honest about.

Pituitary desensitization. Sustained agonism of the ghrelin receptor may cause downregulation over time, reducing native GH pulsatility after discontinuation. Case reports of prolonged post-cycle blunting of GH response exist but have not been quantified in controlled studies.

Incidence Summary Table

| Side Effect | Incidence (Treated) | Incidence (Placebo) | Primary Source | |---|---|---|---| | Peripheral edema | ~50% | ~20% | Nass 2008 | | Impaired fasting glucose | 18% | 0% | Copeland 2010 | | Arthralgia | ~12% | ~6% | Nass 2008 | | Somnolence | ~9% | ~2% | Van der Lely 2004 | | Paresthesias | ~8% | ~3% | Nass 2008 | | Heart failure hospitalization | 7.8% | 2.7% | Adunsky 2011 | | Elevated cortisol | ~34% | Not reported | Chapman 1996 |

Who This Is Right For and Who It Is Not

This section is framed by life stage because the risk-benefit equation shifts considerably depending on where a woman is hormonally.

Reproductive-Age Women (Approximately Ages 18-40)

The case for MK-677 in healthy premenopausal women is weak. IGF-1 levels are already higher in premenopausal women than in postmenopausal women. The glucose risk is real. The breast cancer signal from high IGF-1 is specifically documented in premenopausal women. Pregnancy must be reliably prevented. No dosing data in this population exists.

Women in this age group being treated for GH deficiency (a distinct clinical diagnosis) should be managed with pharmaceutical-grade recombinant GH under endocrinologist supervision, not investigational oral secretagogues.

Women with PCOS

MK-677 is a poor fit for most women with PCOS. The insulin resistance that defines metabolic PCOS would likely worsen. IGF-1 can stimulate ovarian androgen production via theca cell IGF-1 receptors, as described in detail in Franks et al., potentially aggravating hyperandrogenism, acne, and hirsutism.

Perimenopause (Approximately Ages 45-55)

This is where most of the existing trial data sits: older adults with declining GH secretion, reduced lean mass, and increased adiposity. The rationale is strongest here, but so is the cardiovascular and glucose risk. Women in perimenopause considering MK-677 should be screened for prediabetes (HbA1c, fasting glucose), cardiac risk factors, and existing edema before any trial.

The Menopause Society's 2023 position on non-hormonal approaches to menopause management does not list GH secretagogues as a recommended or evidence-supported option for perimenopausal symptoms.

Postmenopause

The Adunsky 2011 cardiac signal was observed in postmenopausal women (and older men). This is the population at greatest cardiovascular risk from fluid retention and IGF-1-mediated remodeling. Use in postmenopausal women with any cardiac history is not supportable on current evidence.

Evidence Gap Disclosure

The majority of MK-677 trial participants have been men or postmenopausal women. Premenopausal women, women on combined oral contraceptives (which alter GH secretion and IGF-1), and women during perimenopause with varying hormonal status are not adequately represented in any published trial. Doses, pharmacokinetics, and side-effect incidence rates extrapolated from mixed-sex or predominantly male populations may not apply to cycling women. This is not a hypothetical concern. It is a documented gap in the literature, and any clinician or content site that presents MK-677 data as equally applicable to women without flagging this gap is misrepresenting the evidence base.

Dosing and Timing: What Trials Used vs. What Grey-Market Products Offer

The standard trial dose was 25 mg once daily. Svensson et al. 1998 studied doses from 10 to 50 mg; side effects, particularly glucose and fluid effects, were dose-dependent. Most online formulations sell 10 mg or 25 mg capsules, aligning with trial doses but without quality control, purity assurance, or pharmaceutical-grade manufacturing.

Grey-market products have been found in independent testing to contain inaccurate doses, contaminants, or no active compound at all. The FDA has issued warning letters to companies marketing ibutamoren as a dietary supplement, noting that it does not meet the statutory definition of a dietary supplement.

The practical implication: women purchasing MK-677 online are taking an unapproved investigational compound of uncertain purity at a dose informed by trials conducted mostly in men.

What to Watch For If You Are Currently Taking MK-677

If you are currently using MK-677, these are the monitoring parameters that correspond directly to the documented side effects:

• Fasting glucose or HbA1c at baseline and every three months
• Blood pressure and weight at each check-in (fluid retention marker)
• Symptom screen for paresthesias in hands, particularly upon waking
• Breast tenderness as a reason to pause and consult a clinician
• Any ankle swelling or shortness of breath requires prompt medical evaluation

"There is no approved dose of ibutamoren for women because no regulatory body has reviewed the data as sufficient for approval in any population," said Maya Okafor, MD, WomanRx medical reviewer and board-certified OB-GYN. "Women should not interpret the existence of clinical trials as equivalent to proof of safety or efficacy for off-label personal use."

If you have PCOS, insulin resistance, a personal or family history of hormone-receptor-positive breast cancer, or any cardiovascular diagnosis, the current evidence profile does not support a favorable risk-benefit ratio for MK-677 regardless of dose.